Medications to lower breast cancer risk
By Mayo Clinic staff
In 2023 in the U.S., an estimated 297,790 people were diagnosed with breast cancer and 43,170 people died from the disease. Fortunately, survival rates have increased due to early detection and prevention of the disease.
Breast cancer causes are multifactorial. Some risk factors can be lowered through changes like eating a healthy diet, exercising and avoiding alcohol and tobacco. Other factors are out of a person's control like genetics and family history.
Assessing breast cancer risk
Estimating breast cancer risk is complicated. At Mayo Clinic, teams use different assessment scales to help patients understand their personal risk for cancer.
The Breast Cancer Risk Assessment Tool, also called the Gail Model, and the IBIS Risk Assessment Tool, also called the Tyrer-Cuzick Model, are two of these assessment scales. The models examine multiple factors, and taken together can give an estimate of a person's breast cancer risk.
Some of the factors that play a role in risk assessment for developing breast cancer include:
- Genetic alteration, such as a BRCA1 or BRCA2 mutation
- Previous treatment with chest radiation before age 30
- Prior breast biopsy showing atypical ductal hyperplasia (ADH), lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS)
- Strong family history of breast cancer
Increased breast density also is a risk factor for breast cancer and is incorporated into risk assessment.
Being identified as having a higher risk for developing breast cancer doesn't mean you will get cancer. However, you can understand your personal risk and work with your healthcare team to develop options for prevention and screening.
Medications to reduce risk
Medications are available that can reduce a woman's risk of developing breast cancer. If you have been identified by your breast care team as eligible based on your risk assessment, this option may be offered to you.
Risk-reducing medication is not recommended for people at a low-to-moderate risk of developing breast cancer and is not a replacement for screenings.
It's offered as an option to women at a higher risk of developing cancer and used in addition to the recommended screenings. It's critical to thoroughly discuss the options, benefits, risks and side effects of any medication with your healthcare team before making any decision.
There are two primary categories of medications to reduce breast cancer risk. Estrogen is thought to act as a fuel that promotes the growth of cancer cells.
Risk-reducing medications block estrogen in the body in different ways:
- Selective estrogen receptor modulators (SERM)
Tamoxifen is a SERM. It binds to an estrogen receptor on a cell. Tamoxifen is an option for premenopausal and menopausal women. The most common side effects include hot flashes, vaginal dryness and joint pain. Less common side effects include increased risk for blood clots, stroke and uterine cancer.
- Aromatase inhibitors
These medications decrease the production of estrogen in the body and are an option for postmenopausal women. Side effects include hot flashes, vaginal dryness, joint pain and bone loss leading to osteoporosis. Aromatase inhibitors are not associated with a higher risk for blood clots, stroke or uterine cancer.
SERM and aromatase inhibitors are not taken together. The decision to take one of these medications should be based on your medical history, and the side effects and risks associated with the medication.
Talk with your healthcare team to assess your risk factors for breast cancer and discuss whether to use medication as part of your breast cancer screening and prevention path. — Caroline Clune, M.D., is an internal medicine physician who cares for patients at the Center for Breast Care in La Crosse, Wisconsin.
Also, read these articles:
- "Breast cancer prevention: How to reduce your risk"
- "Breast cancer chemoprevention: Drugs that reduce risk"
- "What does a diagnosis of dense breasts mean?"
- "Breast health during menopause"
- "Mayo Clinic’s DNA study reveals BRCA1 mutations in 3 sisters, prompts life-changing decisions"
- "Beyond BRCA1/2: Pinpointing the risk of inherited breast cancer genes"
- "When to start regular breast cancer screenings"
A version of this article was originally published on the Mayo Clinic Health System blog.